STF-31

STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells[1][2].

Product Specifications

CAS Number

[724741-75-7]

UNSPSC

12352005

Hazard Statement

H302

Target

Autophagy; GLUT

Type

Reference compound

Related Pathways

Autophagy; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/STF-31.html

Purity

99.79

Solubility

DMSO : ≥ 34 mg/mL

Smiles

O=C(NC1=CC=CN=C1)C2=CC=C(CNS(=O)(C3=CC=C(C(C)(C)C)C=C3)=O)C=C2

Molecular Formula

C23H25N3O3S

Molecular Weight

423.53

Precautions

H302

References & Citations

[1]Chan DA, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011 Aug 3;3 (94) :94ra70.|[2]Dedda CD, et al. Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses. International Journal of Molecular Sciences. 2019 Oct 8; 20 (19) :4962.|[3]Wang L, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. Molecular Neurodegeneration, 2019 Jan 11; 14 (1) :2.|[4]Morioka S, et, al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 2018 Nov;563 (7733) :714-718.